Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History CORT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics CORT

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Corcept Therapeutics Incorporated

CORT
Current price
72.01 USD +0.93 USD (+1.31%)
Last closed 68.16 USD
ISIN US2183521028
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 7 663 872 000 USD
Yield for 12 month +131.02 %
1Y
3Y
5Y
10Y
15Y
CORT
21.11.2021 - 28.11.2021

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California. Address: 101 Redwood Shores Parkway, Redwood City, CA, United States, 94065

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

138.25 USD

P/E Ratio

62.84

Dividend Yield

Financials CORT

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures CORT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+675 040 000 USD

Last Year

+482 375 000 USD

Current Quarter

+157 214 000 USD

Last Quarter

+181 890 000 USD

Current Year

+664 158 000 USD

Last Year

+475 894 000 USD

Current Quarter

+154 811 000 USD

Last Quarter

+178 934 000 USD
EBITDA 111 327 000 USD
Operating Margin TTM 2.17 %
Price to Earnings 62.84
Return On Assets TTM 9.18 %
PEG Ratio 0.61
Return On Equity TTM 21.77 %
Wall Street Target Price 138.25 USD
Revenue TTM 685 446 016 USD
Book Value 6.45 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 7.10 %
Dividend Yield
Gross Profit TTM 674 195 968 USD
Earnings per share 1.15 USD
Diluted Eps TTM 1.15 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY -32.00 %
Profit Margin 19.55 %

Stock Valuation CORT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 62.84
Forward PE 55.87
Enterprise Value Revenue 10.58
Price Sales TTM 11.18
Enterprise Value EBITDA 64.45
Price Book MRQ 11.07

Technical Indicators CORT

For 52 Weeks

29.42 USD 117.33 USD
50 Day MA 72.65 USD
Shares Short Prior Month 12 635 387
200 Day MA 60.90 USD
Short Ratio 9.21
Shares Short 12 652 014
Short Percent 16.08 %